Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

2019 New England Journal of Medicine 1,929 citations

Abstract

Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective. (Funded by Vertex Pharmaceuticals; VX17-445-102 ClinicalTrials.gov number, NCT03525444.).

Keywords

IvacaftorCystic fibrosisMedicineCystic fibrosis transmembrane conductance regulatorPlaceboInternal medicinePathology

MeSH Terms

AdolescentAdultAminophenolsBenzodioxolesChildChloride Channel AgonistsChloridesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDouble-Blind MethodDrug CombinationsFemaleForced Expiratory VolumeGenotypeHumansIndolesMaleMutationPyrazolesPyridinesPyrrolidinesQuinolonesSweatYoung Adult

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
article
Volume
381
Issue
19
Pages
1809-1819
Citations
1929
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1929
OpenAlex
81
Influential
1785
CrossRef

Cite This

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. (2019). Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine , 381 (19) , 1809-1819. https://doi.org/10.1056/nejmoa1908639

Identifiers

DOI
10.1056/nejmoa1908639
PMID
31697873
PMCID
PMC7282384

Data Quality

Data completeness: 90%